Medirom Healthcare Tech released FY2024 Q3 earnings on April 29, 2025 (EST) with actual revenue of USD 16.96 M and EPS of USD 0.3877
Brief Summary
Medirom Healthcare Tech reported 16.96 million USD in revenue and an EPS of 0.3877 USD for its 2024 fiscal year Q3, without further expectations or comparisons available.
Impact of The News
Medirom Healthcare Tech’s financial briefing indicates a revenue of 16.96 million USD and an EPS of 0.3877 USD for its third quarter of the 2024 fiscal year.
Comparison with Market Expectations: There is no explicit mention of market expectations in the references, thus it’s unclear if these figures are above or below predicted values.
Comparison with Peers: The references provide financial data from peer companies such as Regeneron Pharmaceuticals, which reported a total revenue of 3 billion USD for Q1 2025 with an EPS of 7.27 USD Reuters. Crown Holdings also showed significant growth, with a Q1 2025 net income of 193 million USD and an EPS of 1.65 USD Reuters. Given these figures, Medirom’s performance seems modest.
Business Status and Trends: Medirom’s reported figures provide a snapshot of its current financial health, but lack contextual benchmarks such as growth rates or comparison to previous quarters. The absence of such data makes it difficult to infer specific business trends. However, maintaining profitability with a positive EPS suggests stable operational performance.
Transmission Path: The financial results could influence investor sentiment and stock prices, especially if compared against peer performances or historical data. The disclosure might affect the company’s market positioning and future investment attractiveness, further impacting stock valuation.
